Departamento de Patología, Facultad de Medicina, Universitat de València, Avda Blasco Ibáñez 15, 46010, Valencia, Spain.
Fundación de Investigación del Hospital Clínico Universitario de Valencia / INCLIVA, Valencia, Spain.
Cell Oncol (Dordr). 2017 Aug;40(4):389-399. doi: 10.1007/s13402-017-0329-5. Epub 2017 Jun 19.
Glioblastoma (GB) is the most frequent and most malignant primary brain tumor in adults. Previously, it has been found that both genetic and epigenetic factors may play critical roles in its etiology and prognosis. In addition, it has been found that the epidermal growth factor receptor gene (EGFR) is frequently over-expressed and amplified in primary GBs. Here, we assessed the promoter methylation status of 10 genes relevant to GB and explored associations between these findings and the EGFR gene amplification status.
Tumor samples were obtained from 36 patients with primary GBs. In addition, 6 control specimens were included from patients who were operated for diseases other than brain tumors. The amplification status of the EGFR gene, and its deletion mutant EGFRvIII, were evaluated using FISH and MLPA, respectively. The IDH1/2 gene mutation status was verified using Sanger sequencing. A commercial DNA methylation kit was used to assess the promoter methylation status of 10 pre-selected genes. Metabolic profiles were measured using HR-MAS NMR spectroscopy. The EGFR and ARF1 mRNA expression levels were quantified using qRT-PCR.
Of the 10 genes analyzed, we found that only ARF1 promoter hypermethylation was significantly associated with EGFR gene amplification. ARF1 is a GTPase that is involved in vesicle trafficking and the Golgi apparatus. Subsequent tumor metabolism measurements revealed a positive association between EGFR amplification and different membrane precursors and methyl-donor metabolites. Finally, we found that EGFR gene amplifications were associated with distinct tumor infiltration patterns, thus representing a putative novel functional association between EGFR gene amplification and ARF1 gene promoter methylation in GB.
The results reported here provide a basis for a new hypotheses connecting EGFR gene amplification in GB cells with ARF1 gene promoter methylation, vesicle trafficking, membrane turnover and tumor metabolism. The mechanism(s) underlying these connections and their functional consequences remain to be established.
胶质母细胞瘤(GB)是成人中最常见和最恶性的原发性脑肿瘤。此前发现,遗传和表观遗传因素都可能在其病因和预后中发挥关键作用。此外,已发现表皮生长因子受体基因(EGFR)在原发性 GB 中经常过度表达和扩增。在这里,我们评估了 10 个与 GB 相关的基因的启动子甲基化状态,并探讨了这些发现与 EGFR 基因扩增状态之间的关联。
从 36 名原发性 GB 患者中获得肿瘤样本。此外,从因非脑部肿瘤而接受手术的患者中纳入 6 个对照标本。使用 FISH 和 MLPA 分别评估 EGFR 基因的扩增状态及其缺失突变 EGFRvIII。使用 Sanger 测序验证 IDH1/2 基因突变状态。使用商业 DNA 甲基化试剂盒评估 10 个预选基因的启动子甲基化状态。使用 HR-MAS NMR 光谱法测量代谢谱。使用 qRT-PCR 定量 EGFR 和 ARF1 mRNA 表达水平。
在所分析的 10 个基因中,我们发现只有 ARF1 启动子超甲基化与 EGFR 基因扩增显著相关。ARF1 是一种参与囊泡运输和高尔基体的 GTPase。随后的肿瘤代谢测量显示,EGFR 扩增与不同的膜前体和甲基供体代谢物之间存在正相关。最后,我们发现 EGFR 基因扩增与不同的肿瘤浸润模式相关,因此代表了 EGFR 基因扩增与 GB 中 ARF1 基因启动子甲基化之间的一种新的潜在功能关联。
这里报告的结果为一个新的假设提供了依据,该假设将 GB 细胞中的 EGFR 基因扩增与 ARF1 基因启动子甲基化、囊泡运输、膜周转率和肿瘤代谢联系起来。这些关联的机制及其功能后果仍有待确定。